AKT1 and neoplasm: Due to AKT’s role in a variety of human solid tumors and hematological malignancies, several therapies have been developed to target components of the AKT pathway to reduce tumor survival such as: Wortmannin and LY294002, which are reversible and non-reversible inhibitors of PI3K, respectively.